The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-4329
+8 800 250-18-12
  • (toll-free number for subscriptions)
    Mon-Fri from 10 a.m. to 6 p.m.

  • © 1998-2025
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Kogan E.A.

Sechenov First Moscow State Medical University

Shchelokova E.E.

Sechenov First Moscow State Medical University

Demura T.A.

Sechenov First Moscow State Medical University

Zharkov N.V.

Sechenov First Moscow State Medical University

Avraamova S.T.

Sechenov First Moscow State Medical University

Kovyazina N.V.

The Russian University of Medicine (RosUniMed)

Meerovich G.A.

Sechenov First Moscow State Medical University;
A.M. Prokhorov General Physics Institute Russian Academy of Sciences

Meerovich I.G.

Federal Research Centre «Fundamentals of Biotechnology»

Ermakova E.A.

Sechenov First Moscow State Medical University

Kholschenkova A.E.

Sechenov First Moscow State Medical University

Reshetov I.V.

I.M. Sechenov First Moscow State Medical University (Sechenov University) of the Ministry of Health of Russia

Heterogeneity of ALDH1, CD133 and CD34 expression in cancer stem cells of lung adenocarcinoma

Authors:

Kogan E.A., Shchelokova E.E., Demura T.A., Zharkov N.V., Avraamova S.T., Kovyazina N.V., Meerovich G.A., Meerovich I.G., Ermakova E.A., Kholschenkova A.E., Reshetov I.V.

More about the authors

Journal: Russian Journal of Archive of Pathology. 2025;87(5): 36‑45

DOI: 10.17116/patol20258705136

Read: 403 times

Download PDF (RU)
Contact the author
Table of contents

HETEROGENEITY OF ALDH1, CD133 AND CD34 EXPRESSION IN CANCER STEM CELLS OF LUNG ADENOCARCINOMA
HETEROGENEITY OF ALDH1, CD133 AND CD34 EXPRESSION IN CANCER STEM CELLS OF LUNG ADENOCARCINOMA

To cite this article:

Kogan EA, Shchelokova EE, Demura TA, et al. . Heterogeneity of ALDH1, CD133 and CD34 expression in cancer stem cells of lung adenocarcinoma. Russian Journal of Archive of Pathology. 2025;87(5):36‑45. (In Russ.)
https://doi.org/10.17116/patol20258705136

Подписка 2026 Архив патологии (Russian Journal of Archive of Pathology)
МСФ на ЯМ
Использование инфографики авторами научных работ
Close metadata
Recommended articles:
Comparative analysis of morphometric and histological characteristics of HPV-associated and HPV-independent vulvar squamous cell carcinoma. Russian Journal of Archive of Pathology. 2025;(3):26-32
Redu­ction of cyto­skeleton gene expression in tumor cells during lentivirus transduction. Mole­cular Gene­tics, Microbiology and Viro­logy. 2025;(1):30-37
Abstract:

Lung adenocarcinoma (LAC) is one of the leading causes of cancer mortality, which is most likely due to the presence of cancer stem cells (CSC) in the tumor, which form a heterogeneous hierarchy and are responsible for the occurrence and progression of carcinoma, as well as its unfavorable prognosis. The ability of CSC to form heterogeneous tumor populations in lung cancer has not been sufficiently studied.

OBJECTIVE

Detection of cancer cells with signs of stemness in LAC and establishment of their heterogeneity by expression of ALDH1, CD133 and CD34 markers in surgical material depending on the histological type, degree of malignancy and stage of the tumor process, as well as in the A549 cell culture.

MATERIAL AND METHODS

Clinical and morphological analysis of surgical material of LAC from 32 patients was performed, and the culture of lung adenocarcinoma cells A549 was studied. Stem cell markers ALDH1, CD133 and CD34 were detected in the analyzed material by immunohistochemistry. The percentage of positively stained cells was calculated in the preparations.

RESULTS

In all cases of ALCL, CSCs containing ALDH1, CD133 and CD34 were found both in the surgical material and in the A549 cell culture. Heterogeneity of CSCs for the studied markers was established. In patients with early stages of cancer without metastases in the lymph nodes, the number of ALDH1+ CSCs predominated in the primary tumor tissue. With the appearance of metastases in the regional lymph nodes, a significant increase in the number of cells with positive staining in reactions with antibodies to CD34 was found in the ALCL tissue. In patients with metastatic cancer, staining of the overwhelming majority of tumor cells was detected in reactions with all markers — ALDH1, CD133 and CD34.

CONCLUSION

In ACL, both in the surgical material and in the A549 culture, CSCs expressing the stemness markers ALDH1, CD133 and CD34 were detected. An increase in the number of CSCs expressing the stemness markers ALDH1, CD34 and CD133 in the tumor tissue occurs with carcinoma progression. In ACL, heterogeneity of CSCs by the studied markers is noted: at early stages in patients without metastases in the lymph nodes, ALDH1+ CSCs predominate in the tumor tissue, while with the appearance of metastatic lesions of the lymph nodes, CD34+ CSC populations dominate. Quantitative heterogeneity is also observed in the A549 cell culture: the largest number was CD34+ CSCs, slightly less ALDH1+ CSCs and a minimum number of cells with CD133+ CSCs.

Keywords:

cancer stem cells
lung adenocarcinoma
carcinogenesis
ALDH1
CD133
CD34
CSC heterogeneity

Authors:

Kogan E.A.

Sechenov First Moscow State Medical University

Shchelokova E.E.

Sechenov First Moscow State Medical University

Demura T.A.

Sechenov First Moscow State Medical University

Zharkov N.V.

Sechenov First Moscow State Medical University

Avraamova S.T.

Sechenov First Moscow State Medical University

Kovyazina N.V.

The Russian University of Medicine (RosUniMed)

Meerovich G.A.

Sechenov First Moscow State Medical University;
A.M. Prokhorov General Physics Institute Russian Academy of Sciences

Meerovich I.G.

Federal Research Centre «Fundamentals of Biotechnology»

Ermakova E.A.

Sechenov First Moscow State Medical University

Kholschenkova A.E.

Sechenov First Moscow State Medical University

Reshetov I.V.

I.M. Sechenov First Moscow State Medical University (Sechenov University) of the Ministry of Health of Russia

Received:

16.06.2025

Accepted:

25.06.2025

Close metadata

References:

  1. Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: A Cancer Journal for Clinicians. 2024;74(3):229‐263.  https://doi.org/10.3322/caac.21834
  2. Phi LTH, Sari IN, Yang YG, Lee SH, Jun N, Kim KS, et al. Cancer Stem Cells (CSCs) in Drug Resistance and their Therapeutic Implications in Cancer Treatment. Stem Cells International. 2018;28:5416923. https://doi.org/10.1155/2018/5416923
  3. Prabavathy D, Swarnalatha Y, Ramadoss N. Lung cancer stem cells—origin, characteristics and therapy. Stem Cell Investigation. 2018;5:6.  https://doi.org/10.21037/sci.2018.02.01
  4. Chu X, Tian W, Ning J, Xiao G, Zhou Y, Wang Z, et al. Cancer stem cells: advances in knowledge and implications for cancer therapy. Signal Transduction and Targeted Therapy. 2024;5;9(1):170.  https://doi.org/10.1038/s41392-024-01851-y
  5. Hardavella G, George R, Sethi T. Lung cancer stem cells-characteristics, phenotype. Translational Lung Cancer Research. 2016; 5(3):272-9.  https://doi.org/10.21037/tlcr.2016.02.01
  6. Mohan A, Raj Rajan R, Mohan G, Kollenchery Puthenveettil P, Maliekal TT. Markers and Reporters to Reveal the Hierarchy in Heterogeneous Cancer Stem Cells. Frontiers in Cell and Developmental Biology 2021;9:668851. https://doi.org/10.3389/fcell.2021.66885
  7. Masciale V, Banchelli F, Grisendi G, D’Amico R, Maiorana A, Stefani A, et al. Cancer Stem Cells and Cell Cycle Genes as Independent Predictors of Relapse in Non-small Cell Lung Cancer: Secondary Analysis of a Prospective Study. STEM CELLS Translational Medicine. 2022;23;11(8):797-804.  https://doi.org/10.1093/stcltm/szac040
  8. Gasch C, Ffrench B, O’Leary JJ, Gallagher MF. Catching moving targets: cancer stem cell hierarchies, therapy-resistance & considerations for clinical intervention. Molecular Cancer. 2017;16, 43.  https://doi.org/10.1186/s12943-017-0601-3
  9. Lei HM, Zhang KR, Wang CH, Wang Y, Zhuang GL, Lu LM, et al. Aldehyde Dehydrogenase 1a1 Confers Erlotinib Resistance Via Facilitating the Reactive Oxygen Species-Reactive Carbonyl Species Metabolic Pathway in Lung Adenocarcinomas. Theranostics 2019;9(24):7122-39.  https://doi.org/10.7150/thno.35729
  10. Amir Barzegar Behrooz, Amir Syahir & Syahida Ahmad. CD133: beyond a cancer stem cell biomarker. Journal of Drug Targeting. 2019;27:3,257-269.  https://doi.org/10.1080/1061186X.2018.1479756
  11. Kapoor S, Shenoy SP, Bose B. CD34 cells in somatic, regenerative and cancer stem cells: Developmental biology, cell therapy, and omics big data perspective. Journal of Cellular Biochemistry. 2020;121(5-6):3058-3069. https://doi.org/10.1002/jcb.29571
  12. Wei Y, Li Y, Chen Y, Liu P, Huang S, Zhang Y, et al. ALDH1: A potential therapeutic target for cancer stem cells in solid tumors. Frontiers in Oncology. 2022;12:1026278. https://doi.org/10.3389/fonc.2022.1026278
  13. MacDonagh L, Santiago RM, Gray SG, Breen E, Cuffe S, Finn SP, et al. Exploitation of the vitamin a/retinoic acid axis depletes ALDH1-positive cancer stem cells and re-sensitises resistant non-small cell lung cancer cells to cisplatin. Translational Oncology. 2021;14(4):101025. https://doi.org/10.1016/j.tranon.2021.101025
  14. Hida K, Maishi N, Akiyama K, Ohmura-Kakutani H, Torii C, Ohga N, et al. Tumor endothelial cells with high aldehyde dehydrogenase activity show drug resistance. Cancer Science. 2017; 108(11):2195-2203. https://doi.org/10.1111/cas.13388
  15. Zanoni M, Bravaccini S, Fabbri F, Arienti C. Emerging Roles of Aldehyde Dehydrogenase Isoforms in Anti-cancer Therapy Resistance. Frontiers in Medicine 2022;1;9:795762. https://doi.org/10.3389/fmed.2022.795762
  16. Moreno-Londoño AP, Robles-Flores M. Functional Roles of CD133: More than Stemness Associated Factor Regulated by the Microenvironment. Stem Cell Reviews and Reports. 2024;20(1):25-51.  https://doi.org/10.1007/s12015-023-10647-6
  17. Roy S, Lu K, Nayak MK, Bhuniya A, Ghosh T, Kundu S, et al. Activation of D2 Dopamine Receptors in Cd133+Ve Cancer Stem Cells in Non-Small Cell Lung Carcinoma Inhibits Proliferation, Clonogenic Ability, and Invasiveness of These Cells. Journal of Biological Chemistry. 2017;292(2):435-45.  https://doi.org/10.1074/jbc.M116.748970
  18. Pleskač P, Fargeas CA, Veselska R, Corbeil D, Skoda J. Emerging roles of prominin-1 (CD133) in the dynamics of plasma membrane architecture and cell signaling pathways in health and disease. Cellular & Molecular Biology Letters. 2024;29:41.  https://doi.org/10.1186/s11658-024-00554-0
  19. Radu P, Zurzu M, Paic V, Bratucu M, Garofil D, Tigora A, et al. CD34—Structure, Functions and Relationship with Cancer Stem Cells. Medicina. 2023;59(5):938.  https://doi.org/10.3390/medicina59050938
  20. Hassanpour M, Salybekov AA, Kobayashi S, Asahara T. CD34 positive cells as endothelial progenitor cells in biology and medicine. Frontiers in Cell and Developmental Biology. 2023;11:1128134. https://doi.org/10.3389/fcell.2023.1128134
  21. Dawood S, Austin L, Cristofanilli M. Cancer stem cells: Implications for cancer therapy. Oncology. 2014;28:1101-1107 
  22. Zheng Y, Wang L, Yin L, Yao Z, Tong R, Xue J, et al. Lung Cancer Stem Cell Markers as Therapeutic Targets: An Update on Signaling Pathways and Therapies. Frontiers in Oncology. 2022:12:873994. https://doi.org/10.3389/fonc.2022.873994
  23. Lathia J, Liu H, Matei D. The Clinical Impact of Cancer Stem Cells. The Oncologist. 2020;25(2):123-131.  https://doi.org/10.1634/theoncologist.2019-0517
  24. Walcher L, Kistenmacher AK, Suo H, Kitte R, Dluczek S, Strauß A, et al. Cancer stem cells: origins and biomarkers—perspectives for targeted personalized therapies. Frontiers in Immunology. 2020; 11:1280. https://doi.org/10.3389/fimmu.2020.01280
  25. Korzhevskij D.E. Osnovy gistologicheskoj tekhniki. Prakticheskoe rukovodstvo. M.: Medicina; 2010. (In Russ.).
  26. Dabbs DJ. Diagnostic Immunohistochemistry. New York: Churchill Livingstone; 2002.
  27. Lemeshko B.Y. Criteria for testing hypotheses about uniformity. Application manual. M.: INFRA-M, 2021. (In Russ.). https://doi.org/10.12737/986695
  28. WHO Classification of Tumours. Thoracic tumours. WHO classification of tumours editorial board. 5th ed. Vol. 5. France, Lyon: IARC; 2021. https://tumourclassification.iarc.who.int
Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Contact us
If you have any questions, complaints or suggestions, please use this feedback form.
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.
Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.